Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BCAB

BCAB - BioAtla, Inc. Stock Price, Fair Value and News

$0.31-0.01 (-3.13%)
Market Closed

72/100

BCAB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

72/100

BCAB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.52

Target 3M

$0.39

Target 6M

$0.44

BCAB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCAB Price Action

Last 7 days

3.3%

Last 30 days

-60.3%

Last 90 days

-55.1%

Trailing 12 Months

-35.4%

BCAB RSI Chart

BCAB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCAB Valuation

Market Cap

18.2M

Price/Earnings (Trailing)

-0.28

Price/Sales (Trailing)

1.71

Price/Free Cashflow

-0.32

BCAB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.52

Target 3M

$0.39

Target 6M

$0.44

BCAB Fundamentals

BCAB Revenue

Revenue (TTM)

11.0M

BCAB Earnings

Earnings (TTM)

-64.7M

Earnings Growth (Yr)

-49.05%

Earnings Growth (Qtr)

15.68%

BCAB Profitability

Return on Equity

-11.8K%

Return on Assets

-406.76%

Free Cashflow Yield

-313.14%

BCAB Investor Care

Shares Dilution (1Y)

21.63%

Diluted EPS (TTM)

-1.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024007.5M11.0M
20210590.0K400.0K3.9M
20204.0M2.8M1.6M429.0K
20190005.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About BioAtla, Inc.

BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
 CEO
 WEBSITEbioatla.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES66

BioAtla, Inc. Frequently Asked Questions

BCAB is the stock ticker symbol of BioAtla, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of BioAtla, Inc. is 18.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BCAB's fair value in chart for subscribers.

The fair value guage provides a quick view whether BCAB is over valued or under valued. Whether BioAtla, Inc. is cheap or expensive depends on the assumptions which impact BioAtla, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCAB.

As of Wed Jan 28 2026, BCAB's PE ratio (Price to Earnings) is -0.28 and Price to Sales (PS) ratio is 1.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCAB PE ratio will change depending on the future growth rate expectations of investors.